© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 30, 2016, the consensus forecast amongst 24 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 20 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 115.00, with a high estimate of 135.00 and a low estimate of 81.00. The median estimate represents a 34.00% increase from the last price of 85.82. View Full Financials
In 2015, Gilead Sciences Inc reported a dividend of 1.29 USD. The 12 analysts covering the company expect dividends of 1.86 USD for the upcoming fiscal year, an increase of 44.11%. View Full Financials
|Div growth (TTM)||--|
On Apr 28, 2016, Gilead Sciences, Inc. reported 1st quarter 2016 earnings of 3.03 per share. This result was in line with the consensus of the 23 analysts following the company and exceeded last year's 1st quarter results by 3.06%.
The next earnings announcement is expected on Jul 26, 2016. View Full Interim Financials
|Average growth rate||+0.93 %|
Gilead Sciences, Inc. reported annual 2015 earnings of 12.61 per share on Feb 02, 2016. View Full Annual Financials
|Average growth rate||+89.52 %|
Gilead Sciences Inc. had 1st quarter 2016 revenues of 7.79bn. This missed the 8.12bn consensus estimate of the 18 analysts following the company. This was 2.63% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+0.84 %|
Gilead Sciences Inc. had revenues for the full year 2015 of 32.64bn. This was 31.13% above the prior year's results. View Full Annual Financials
|Average growth rate||+46.12 %|